Novartis shares fall after second major trial setback in days

Novartis said its experimental treatment for a muscle-wasting disorder failed a late-stage clinical trial, marking its second major trial setback within days. The news drove Novartis shares down about 9%, among the Swiss drugmaker's worst trading days on record, and raises pipeline-execution concerns.